On Wednesday, November 20, the UN Climate Conference (COP29) in Baku, Azerbaijan, spotlighted urbanization and transportation as critical areas for climate action. The day emphasized the pivotal role of cities and towns in reducing global emissions and advancing public health.…
CVS Health is the first healthcare company to receive Health Equity accreditation from URAC, recognizing the work done through CVS Caremark and CVS Specialty. URAC sets high standards in healthcare quality, covering clinical practice, consumer protections, performance measurement, operations infrastructure,…
Novartis has secured the top spot in the 2024 Access to Medicine Index (ATMI), highlighting the company’s leadership in enhancing global access to medicines. The Access to Medicine Index, published biennially, is an independent report that evaluates the efforts of…
Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, today announced positive topline results from the pivotal Phase 3 MK-3475A-D77 trial, which assessed the noninferiority of subcutaneous pembrolizumab, Merck’s anti-PD-1 therapy, combined with chemotherapy, versus intravenous (IV) KEYTRUDA…
Celltrion presented new findings from Phase III randomized controlled trials (RCTs) for its biosimilar candidates CT-P41 (referencing PROLIA®/XGEVA® for postmenopausal osteoporosis) and CT-P47 (referencing ACTEMRA® for moderate-to-severe rheumatoid arthritis) at the American College of Rheumatology (ACR) Convergence 2024 in Washington,…
As world leaders gather in Rio de Janeiro, Brazil, for the G20 Summit this weekend, the city’s iconic Christ the Redeemer statue will be bathed in teal light in a symbolic show of support for the global fight against cervical…
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Non-Epithelioid Malignant Pleural Mesothelioma (MPM) Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, announced that the European Medicines Agency’s…
Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today shared more data on the challenges Americans are facing when trying to access branded GLP-1 medication and introduced a GLP-1 Supply Tracker, where individuals…
QPS Holdings, LLC announced today that their Springfield campus, QPS Missouri, has launched a new Cell Therapy business unit. The unit’s first achievement is the opening of a new Leukopak collection and blood product processing center. This facility is designed…
Business Leaders and Industry Experts Join Top Policymakers to Address Pivotal Issues in Health Globally at the Milken Institute 2024 Future of Health Summit The Milken Institute 2024 Future of Health Summit opens today, gathering hundreds of renowned business leaders, health experts,…
Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752), which is studying twice-yearly lenacapavir, the company’s injectable HIV-1 capsid inhibitor, for the investigational use of HIV…
VIVOLTA, the medical electrospinning solutions provider, has signed a long-term partnership with Neurochase, the CNS (central nervous system) delivery platform specialist, to manufacture electrospun micro-catheters to deliver advanced therapies to the brain.UK-based Neurochase is a medical technology company developing a…